Fact checked by Nick Blackmer Weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Weight-loss drugs could soon be used to treat depression following a landmark study. The startling research raises the ...

Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...

The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...

North Carolina is facing a $500 million dollar problem. State officials say the state is running out of money to pay for the state health insurance plan for workers which means 750,000 state workers ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...